journal article·2016-03-02

Modification of Titanium Substrates with Chimeric Peptides Comprising Antimicrobial and Titanium-Binding Motifs Connected by Linkers To Inhibit Biofilm Formation

Zihao Liu, Shiqing Ma, Shun Duan, Deng Xuliang, Yingchun Sun, Xi Zhang, Xinhua Xu, Binbin Guan, Chao Wang, Meilin Hu, Xingying Qi, Xu Zhang, Ping Gao

Publisher page

Abstract

Bacterial adhesion and biofilm formation are the primary causes of implant-associated infection, which is difficult to eliminate and may induce failure in dental implants. Chimeric peptides with both binding and antimicrobial motifs may provide a promising alternative to inhibit biofilm formation on titanium surfaces. In this study, chimeric peptides were designed by connecting an antimicrobial motif (JH8194: KRLFRRWQWRMKKY) with a binding motif (minTBP-1: RKLPDA) directly or via flexible/rigid linkers to modify Ti surfaces. We evaluated the binding behavior of peptides using quartz crystal microbalance (QCM) and atomic force microscopy (AFM) techniques and investigated the effect of the modification of titanium surfaces with these peptides on the bioactivity of Streptococcus gordonii (S. gordonii) and Streptococcus sanguis (S. sanguis). Compared with the flexible linker (GGGGS), the rigid linker (PAPAP) significantly increased the adsorption of the chimeric peptide on titanium surfaces (p < 0.05). Concentration-dependent adsorption is consistent with a single Langmuir model, whereas time-dependent adsorption is in line with a two-domain Langmuir model. Additionally, the chimeric peptide with the rigid linker exhibited more effective antimicrobial ability than the peptide with the flexible linker. This finding was ascribed to the ability of the rigid linker to separate functional domains and reduce their interference to the maximum extent. Consequently, the performance of chimeric peptides with specific titanium-binding motifs and antimicrobial motifs against bacteria can be optimized by the proper selection of linkers. This rational design of chimeric peptides provides a promising alternative to inhibit the formation of biofilms on titanium surfaces with the potential to prevent peri-implantitis and peri-implant mucositis.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Antimicrobial Peptides and Activities · Biochemical and Structural Characterization · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School and Hospital of Stomatology, Tianjin Medical University, Tianjin 300070, People’s Republic of China

Beijing Laboratory of Biomedical Materials, Beijing University of Chemical Technology, Beijing 100029, People’s Republic of China

Department of Geriatric Dentistry, Peking University School and Hospital of Stomatology, Beijing 100081, People’s Republic of China

School of Materials Science and Engineering, Tianjin University, Tianjin 300072, People’s Republic of China

Funding

Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · Tianjin Research Program of Application Foundation and Advanced Technology

References (64)

Show source-provided references
1. 10.1016/j.biomaterials.2012.01.01810.1016/j.biomaterials.2012.01.018 ↗
2. 10.1111/j.1600-051X.2008.01274.x10.1111/j.1600-051X.2008.01274.x ↗
3. 10.1111/prd.1206910.1111/prd.12069 ↗
4. 10.1159/00025980110.1159/000259801 ↗
5. 10.1128/MMBR.66.3.486-505.200210.1128/MMBR.66.3.486-505.2002 ↗
6. 10.1128/MMBR.00014-0910.1128/MMBR.00014-09 ↗
7. 10.1111/j.1600-0501.2007.01381.x10.1111/j.1600-0501.2007.01381.x ↗
8. 10.1055/s-2000-877810.1055/s-2000-8778 ↗
9. 10.1016/S0142-9612(01)00198-310.1016/S0142-9612(01)00198-3 ↗
10. 10.1007/s10295-005-0066-z10.1007/s10295-005-0066-z ↗
11. 10.1086/37484210.1086/374842 ↗
12. 10.1093/annhyg/mei01910.1093/annhyg/mei019 ↗
13. 10.1016/j.vacuum.2006.12.01110.1016/j.vacuum.2006.12.011 ↗
14. 10.1016/j.apsusc.2007.06.03110.1016/j.apsusc.2007.06.031 ↗
15. 10.1177/0022034599078006080110.1177/00220345990780060801 ↗
16. 10.1038/415389a10.1038/415389a ↗
17. 10.3390/ijms1209597110.3390/ijms12095971 ↗
18. Bush K. · Nat. Rev. Microbiol. · 2011 · 9 · 89410.1038/nrmicro2693 ↗
19. 10.1038/nbt126710.1038/nbt1267 ↗
20. 10.1177/1045441195006002050110.1177/10454411950060020501 ↗
21. 10.1177/0895937400014001020110.1177/08959374000140010201 ↗
22. 10.1111/febs.1261210.1111/febs.12612 ↗
23. 10.1111/j.1601-0825.2004.01010.x10.1111/j.1601-0825.2004.01010.x ↗
24. 10.1007/s10856-011-4440-210.1007/s10856-011-4440-2 ↗
25. 10.3390/ijms1104145810.3390/ijms11041458 ↗
26. 10.1146/annurev.matsci.34.040203.12102510.1146/annurev.matsci.34.040203.121025 ↗
27. 10.1557/mrs2008.10310.1557/mrs2008.103 ↗
28. 10.1006/jmbi.2000.368210.1006/jmbi.2000.3682 ↗
29. 10.1021/la700446g10.1021/la700446g ↗
30. 10.1021/ja038414q10.1021/ja038414q ↗
31. 10.1016/S0167-5729(00)00011-X10.1016/S0167-5729(00)00011-X ↗
32. 10.1016/j.addr.2012.09.03910.1016/j.addr.2012.09.039 ↗
33. 10.1016/0022-2836(90)90085-Z10.1016/0022-2836(90)90085-Z ↗
34. 10.1016/j.pep.2008.04.01310.1016/j.pep.2008.04.013 ↗
35. 10.1021/ja00722a04310.1021/ja00722a043 ↗
36. 10.1007/BF0133793710.1007/BF01337937 ↗
37. 10.5603/FHC.2012.008610.5603/FHC.2012.0086 ↗
38. 10.1002/anie.20080525910.1002/anie.200805259 ↗
39. 10.1021/la060689710.1021/la0606897 ↗
40. 10.1016/j.tibtech.2013.09.00810.1016/j.tibtech.2013.09.008 ↗
41. Sumida S. · Int. J. Oral Max. Impl. · 2001 · 17 · 696
42. 10.1007/s11095-008-9767-010.1007/s11095-008-9767-0 ↗
43. 10.1073/pnas.050006210210.1073/pnas.0500062102 ↗
44. 10.1007/s11095-006-9059-510.1007/s11095-006-9059-5 ↗
45. 10.1111/j.1601-0825.2004.01010.x10.1111/j.1601-0825.2004.01010.x ↗
46. 10.1016/S1359-0294(03)00009-810.1016/S1359-0294(03)00009-8 ↗
47. 10.2144/00011345010.2144/000113450 ↗
48. 10.1016/j.jconrel.2009.09.00710.1016/j.jconrel.2009.09.007 ↗
49. Thorpe P. E. · Cancer Res. · 1987 · 47 · 5924
50. 10.1021/la035475t10.1021/la035475t ↗
51. 10.1021/bc800280u10.1021/bc800280u ↗
52. 10.1016/j.bbamem.2006.07.00110.1016/j.bbamem.2006.07.001 ↗
53. 10.1016/j.chemphyslip.2012.01.00910.1016/j.chemphyslip.2012.01.009 ↗
54. 10.1038/nrmicro209510.1038/nrmicro2095 ↗
55. 10.2174/13816121279927761710.2174/138161212799277617 ↗
56. 10.1074/jbc.272.3.141310.1074/jbc.272.3.1413 ↗
57. 10.1002/prot.34012040710.1002/prot.340120407 ↗
58. 10.1042/bj297024910.1042/bj2970249 ↗
59. 10.1371/journal.ppat.100106710.1371/journal.ppat.1001067 ↗
60. Badiani K. · Int. Pharm. Ind. · 2012 · 4 · 84
61. Howl J. · 2005 · 29810.1385/1592598773 ↗
62. Reichert, J.; Pechon, P.; Tartar, A.; Dunn, M.Development Trends for Peptide Therapeutics; Industry Report;Peptide Therapeutics Foundation:San Diego, 2010.
63. 10.1099/mic.0.026120-010.1099/mic.0.026120-0 ↗
64. 10.1124/pr.55.1.210.1124/pr.55.1.2 ↗